---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000174"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:33.830387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR

## Summary
- Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).
- Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).
- Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.
- 2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.
- 2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M.

## SEC filing metadata
- accession: 0001171843-26-000174
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/0001171843-26-000174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184326000174/f8k_011126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000174
- JSON: https://secwatch.observer/filing/0001171843-26-000174.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.